Palo Alto, California, May 25, 2021 – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up focusing on Nobel Prize-winning technology “induced pluripotent stem cells (iPSCs)” received a third-party certification as US FDA cGMP compliant for its manufacturing facility “Peace Engine Kyoto,” in Kyoto Japan. Peace Engine Kyoto is owned and managed by its sole subsidiary I Peace, Co. Ltd. The facility was awarded a permit in 2020 by Japan’s Ministry of Health, Labour, and Welfare to manufacture specific cell-based products. [Read more…]
Human induced pluripotent stem cell (iPSC)-based models are a valuable resource for studying disease mechanisms in vitro at the cellular level, screening potential new therapeutics, and investigating the propensity and mechanism for the development of toxic side effects caused by a drug treatment. Such iPSC-based models enable research to be performed under defined experimental conditions and in a reproducible manner. [Read more…]
TreeFrog Therapeutics presents new data at the 24th Annual Meeting of the American Society for Cell & Gene Therapy.
Bordeaux, France – May 11, 2021. One month after announcing unprecedented exponential amplification of human pluripotent stem cells (hiPSCs) in a 10L bioreactor French cell therapy company, TreeFrog Therapeutics, today released previously unpublished data at the 24th Annual Meeting of the American Society for Cell & Gene Therapy. The findings compare the continuous expansion over 28 days of human induced pluripotent stem cells (hiPSCs) in 2D cell culture, aggregate culture in bioreactor, and bioreactor-based C-StemTM technology. The benchmark demonstrates that C-StemTM outperforms both the 2D and aggregate cell cultures, with a cumulated amplification of over 151 millionfold over 28 days, achieved in only four passages. [Read more…]
Biomimetic 3D cell culture technology unlocks the manufacturing bottleneck of stem-cell derived cell therapies through exponential hiPSC growth in large-scale bioreactors, with best-in-class cell quality.
Bordeaux, France – April 13th, 2021. French cell therapy company TreeFrog Therapeutics announces unprecedented exponential growth of human induced pluripotent stem cells (hiPSC) in a 10L bioreactor. Using proprietary C-StemTM technology, TreeFrog Therapeutics amplified 50 million hiPSC into a single batch of 15 billion cells in 6.5 days, and company reports exceptional cell quality. Data will be presented at the International Society for Stem Cell Research (ISSCR) Virtual Meeting, taking place June 21 – 26, 2021. [Read more…]
Shoreline Biosciences, a California-based start-up specializing in iPSC-derived cellular immunotherapies for cancer and other serious diseases, announced it has completed an impressive $43M funding round. Founded in 2020 in La Jolla, CA, the company is developing a pipeline of induced pluripotent stem cell (iPSC) derived NK cell and macrophage cell therapy product candidates. The company joins an impressive list of pioneers who are now forging the path toward iPSC-derived cell therapeutics. [Read more…]